Should You Buy Pharma-Bio Serv, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Pharma-Bio Serv, Inc. (PBSV) carries a solid Quality of Company rating of 5.9/10. Trading at $0.54, our multi-model framework evaluates whether the company's financial profile offers a favorable risk-reward setup.
The short answer: 2 of 4 CirclFi valuation models project upside for Pharma-Bio Serv, Inc. (PBSV) at $0.54 — the models are evenly split, with a Quality Score of 5.9/10 and Value-Trap risk of 28/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Pharma-Bio Serv, Inc. (PBSV) in 2026?
What Is the Bull Case vs the Bear Case for Pharma-Bio Serv, Inc. (PBSV)?
| Bull case — $2.91 target (+439.1%) | Bear case — $0.12 target (-77.2%) |
|---|---|
| According to the CirclFi Deep Alpha Valuation Engine, 2 of 4 models identify upside from $0.54 to a median fair value of $0.93, indicating the market hasn't fully priced in Pharma-Bio Serv, Inc.'s earnings power. | According to the CirclFi Deep Alpha Valuation Engine, the ML Residual Income model sees the stock as overvalued with a fair value of $0.12 (-77.2%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, the FTNN Topology model targets a fair value of $2.91 (+439.1%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +516.3% spread between the most bullish and bearish models, signaling elevated analytical uncertainty. |
How Does PBSV Compare to Its Health Information Services Peers?
Valuation data pages: DRIO · SOPH · HTFL · OMDA · CRVW · EVH · BEAT · VASO · SDGR · DOCS · HQY
Which Other Stocks Score Like PBSV on Quality?
Closest companies to PBSV’s Quality of Company score of 5.9/10, across all industries.
- SYRA — Syra Health Corp. (QOC 5.9) · analysis
- SKYH — Sky Harbour Group Corporation (QOC 5.9) · analysis
- AEVA — Aeva Technologies, Inc. (QOC 5.9) · analysis
- ABEO — Abeona Therapeutics Inc. (QOC 5.9) · analysis
- ARCC — Ares Capital Corporation (QOC 5.9) · analysis
- JBDI — JBDI Holdings Limited (QOC 5.9) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Health Information Services Screens Does PBSV Appear In?
So Is Pharma-Bio Serv, Inc. (PBSV) Worth Buying in 2026?
Our models don't have a clear verdict on Pharma-Bio Serv, Inc.. At $0.54 vs. $0.93 median fair value, the median upside of +72.4% masks significant model disagreement (+516.3% spread). With quality at 5.9/10, this is a stock where the margin of error is wide and additional fundamental research is strongly recommended.
These are quantitative model outputs, not investment recommendations. Pharma-Bio Serv, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About PBSV Stock?
Should I buy PBSV stock right now?
Based on CirclFi's multi-model analysis, 2 of 4 models see upside for PBSV at $0.54. The models are divided, which means the investment case depends heavily on your assumptions about Pharma-Bio Serv, Inc.'s future. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Pharma-Bio Serv, Inc.?
Key risks include: limited model coverage (4/13 active), reducing analytical confidence; wide model disagreement (2261% spread), signaling high uncertainty; general market and sector-specific risks affecting Health Information Services companies. Always diversify and consult a financial advisor.
How does PBSV compare to its competitors?
Among Health Information Services peers, PBSV holds a Quality Score of 5.9/10. Comparable companies include DRIO (QOC 6.0), SOPH (QOC 5.9), HTFL (QOC 6.1). The relative ranking helps investors identify whether PBSV offers better fundamental quality than alternatives in the same sector.
Is PBSV a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. PBSV's Quality Score of 5.9/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.
What price should I buy PBSV at?
CirclFi does not provide target buy prices or price alerts. However, our 4 active models produce fair value estimates ranging from $0.12 to $2.91. At $0.54, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for PBSV.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad